Rétatrutide (LY3437943) est un agoniste du polypeptide insulinotrope glucose-dépendant, peptide de type glucagon 1, et les récepteurs du glucagon. Ses relations dose-réponse en ce qui concerne les effets secondaires, sécurité, et l'efficacité pour le traitement de l'obésité n'est pas connue. Methods We conducted a phase 2, en double aveugle, randomisé, placebo-controlled trial involving adults who had a …

Tirzepatide is indicated to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Tirzepatide is also indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management. Tirzepatide has demonstrated significant benefits in obese patients with a …